Contraceptive Technology Update – June 1, 2011
June 1, 2011
View Issues
-
Science alert: HIV drug regimen cuts mother-to-infant transmission
When HIV is not diagnosed until women go into labor, their infants usually are treated soon after birth with the antiretroviral drug zidovudine to prevent infant infection. -
Potential spermicide enters advanced trial
Amphora, under development by Evofem of San Diego, is a bioadhesive acid-buffering gel that coats the vaginal wall and cervix. Amphora helps maintain a woman's natural pH level between 3.8 and 4.2. -
New data emerges on use of hormone therapy
Since results of the 2002 Women's Health Initiative (WHI) report suggested that use of menopausal hormone therapy increases risk of coronary heart disease, science has examined the timing of therapy initiation on safe use of such treatment. -
New test approved for trichomonas vaginalis
Trichomoniasis is the most common curable sexually transmitted infection (STI) in young, sexually active women, according to the Centers for Disease Control and Prevention. An estimated 7.4 million new cases occur each year in U.S. women and men. -
Get your facility ready for HIV Testing Day
Is your facility participating in National HIV Testing Day on June 27? If not, you may be missing an important community outreach opportunity to help people learn their HIV status. -
Teen Topics: Teen relationship abuse puts teens at risk
Four hundred thousand (1.6% of U.S. adolescents) experience serious physical and/or sexual dating violence each year. -
Abstract & Commentary: Predict later weight gain for teens taking DMPA?
The investigators prospectively enrolled and followed a cohort of 97 teens before and six, 12, and 18 months after starting DMPA.